Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
Priothera has raised about $35 million in series A financing to develop drugs for acute myeloid leukemia (AML). The Dublin-based company will use the funds to test mocravimod in a clinical trial of people with AML who are also receiving allogeneic stem cell transplants. Mocravimod is intended to reduce the risk of graft versus host disease and boost the efficacy of the stem cell transplant by targeting sphingosine-1-phosphate receptors. Priothera acquired mocravimod from Kyorin Pharmaceutical, which had licensed it to Novartis.
This article has been sent to the following recipient: